SM
CRBP icon

SG3 Management’s Corbus Pharmaceuticals CRBP Stock Holding History

SG3 Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17
Closed – – 1042
2021
Q4 		$0 Hold
17
– – ﹤0.01% 1076
2021
Q3 		$1K Hold
17
– – ﹤0.01% 948
2021
Q2 		$1K Hold
17
– – ﹤0.01% 977
2021
Q1 		$1K Buy
+17
New +$1.12K ﹤0.01% 1125

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

SG3 Management's CRBP Position: Q1 2022 in Review

SG3 Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2022, closing a stake of 17 shares.

SG3 Management first reported a position in CRBP in Q1 2021 and held it in 4 quarters. The position peaked at $1K in Q3 2021. 72 funds tracked by Wall St. Rank hold CRBP as of Q1 2022.

  • SG3 Management reported no remaining Corbus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 17 Corbus Pharmaceuticals shares in Q1 2022.
  • SG3 Management first reported a position in Corbus Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • SG3 Management's Corbus Pharmaceuticals position peaked at $1K in Q3 2021.
  • 72 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.